Objective: To investigate the anti-tumor mechanism of compound Shuang-zhu (BELY) anti-tumor effect in vitro and in vivo. Method: In experimental evaluation

eight groups were setup: control group

negative control group

six different concentrations of BELY groups (100

80

60

40

20

10

5 μg·mL-1). CCK-8 kit was used to detect the proliferative effect of BELY on K562

MDA-MB-231

LoVo and HepG2 cells. Sixty health kunming mice was used to establish transplant tumor models of murine sarcoma S180 and of H22. Then they were randamly divided into six groups

including control group (NS)

DMSO (1%) group

cisplatin group (1 mg·kg-1)

three different concentration (100

200

400 mg·kg-1) of BELY groups to observe the effect of BELY on tumor-bearing mice. ELISA was employed to detect of cytokines interleukin-2(IL-2)

interleukin-12(IL-6)

interleukin-12(IL-12) and TNF-alpha to reflect the effect of BELY on immune function of tumor-bearing mice. T cell subsets of CD4+and CD8+ in peripheral blood of tumor-bearing mice were measured by flow cytometry. Result: BELY showed a certain degree of inhibition on HepG2 and K562

LoVo

MDA231 cells in dose-effect relationship. BELY could significantly inhibit the growth of the murine sarcoma S180 and of H22

and improve the thymus index

spleen index and body weight of the tumor-bearing mice

BELY could significantly increase serum CD4+/CD8+. Compared with the blank control group

P<0.01 or P<0.05. Conclusion: BELY can not only directly inhibit tumor cells

but also enhance immune to achieve the anti-tumor action bidirectionally.